510(k) Report

510(k) · Cleared

Cleared

Ise Diluent, 1N KCL, Internal Reference and Ise Standards Low and High

K051646510(k) TraditionalCleared Oct 7, 2005108-day reviewClass II21 CFR 862.1665

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Pointe Scientific, Inc., · JGS Electrode, Ion Specific, Sodium

Cleared on Oct 7, 2005 after a 108-day review. FDA’s file for it is a 510(k) statement, which names no predicate.

Decided
Oct 7, 2005
Review
108 days
Class
Class II
Product code
JGS
Recalls
None
Predicates
0

FDA’s file for it is a 510(k) statement, which names no predicate.

FIG. 1 — Lineage of K051646Source: FDA 510(k) database · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA 510(k) statement (indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JGS? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new JGS device

  1. #1 K252475 ABL90 FLEX PLUS Systemscore 12.2 · 4 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against?

FDA’s file for it is a 510(k) statement, which names no predicate.

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

How does its category compare?

All JGS devices

JGS Electrode, Ion Specific, Sodium: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · JGS

3in 2023

2008: 22009: 22010: 12011: 32012: 12013: 22014: 12015: 12016: 42017: 12018: 32019: 32020: 22022: 12023: 32026 (partial year): 1
2007high 4 (2016) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JGS

347in 2023

2011: 191 days median2016: 198 days median2018: 180 days median2019: 58 days median2023: 347 days median
2007high 347 (2023) · low 58 (2019)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · JGS

4in 2023

2007: 72008: 12010: 12011: 12012: 22013: 52015: 12019: 52020: 12021: 12023: 4
2007high 7 (2007) · low 0 (2009)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JGS

64in 2025

2007: 332008: 32009: 572010: 3612011: 9122012: 4122013: 5102014: 2512015: 1582016: 842017: 2922018: 1582019: 1052020: 892021: 912022: 602023: 982024: 962025: 64
2007high 912 (2011) · low 3 (2008)2025

MAUDE reports naming product code JGS, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—733
20082—13
20092—057
20101—1361
201131911912
20121—2412
20132—5510
20141—0251
20151—1158
20164198084
20171—0292
201831800158
20193585105
20202—189
20210—191
20221—060
20233347498
20240—096
20250—064
20261—0—

What is it indicated for?

This product is to be used for the quantitative determination of Electrolytes (Sodium, Potassium and Chloride) in human serum. The determination of Electrolytes is most commonly performed for the diagnosis and treatment of diseases causing an electrolyte imbalance. Sodium determinations are often used in the diagnosis and treatment of a~dosteronism, diabetes insipidus, adrenal hypertension, Addisons disease and a number of other diseases involving…

Read the full statement (108 words)

This product is to be used for the quantitative determination of Electrolytes (Sodium, Potassium and Chloride) in human serum. The determination of Electrolytes is most commonly performed for the diagnosis and treatment of diseases causing an electrolyte imbalance. Sodium determinations are often used in the diagnosis and treatment of a~dosteronism, diabetes insipidus, adrenal hypertension, Addisons disease and a number of other diseases involving electrolyte imbalance. Potassium measurements are used to monitor electrolyte imbalance in the diagnosis and treatment of diseases characterized by low and high potassium levels. Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis.

Indications for use as stated in the FDA 510(k) statement.

Cite this page

510(k) Report. “K051646: Ise Diluent, 1N KCL, Internal Reference and Ise Standards Low and High.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K051646

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Page last updated Nov 3, 2026